Nina Kononenko
Research Subjects
Nina Kononenko has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Aleksandr M. Nikonov
Consultative Diagnostic Center of the Altai Territory
2 shared publications- Anastasia Vechkasova
Diagnostic Center (Medical Genetics)
2 shared publications - Ekaterina Yu. Zakharova
Research Centre for Medical Genetics, 115522 Moscow, Russia
2 shared publications - Elena G. Bakulina
Stavropol Regional Clinical Consultative and Diagnostic Center
2 shared publications Elena V. Osipova
First Republican Clinical Hospital
2 shared publications- Khasyania F. Aksyanova
Nizhny Novgorod Regional Children’s Clinical Hospital
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 25 (4) , 232-247
Clinical and Epidemiological Characteristics of Patients with Mucopolysaccharidosis Type II (Hunter Syndrome) According to Data from the Russian Registry
Background . The study was conducted based on data from the Russian registry of patients with mucopolysaccharidosis (MPS) type II. There are no similar studies based on analysis of data from the national MPS registry in Russian Federation . Objective . The aim of the study is to conduct a comprehensive analysis of MPS type II epidemiology and phenotypic features in Russian patients using data from the national registry, as well as to compare the obtained results with corresponding data from international registries. Methods. The retrospective, cross-sectional observational study included data from 177 patients with confirmed diagnosis of MPS type II. Data on medical history, clinical, laboratory, and instrumental examination methods, as well as data on enzyme replacement therapy (ERT) over the period from 2008 to March 2026 was analyzed. Results . The prevalence of MPS type II in Russian Federation was 0.1 per 100,000 population, and 0.54 per 100,000 live births (approximately 1 in 185,000 live births). The geographical distribution of patients was uneven. The median age of first symptoms was 1.0 (0; 2.0) years, the range — from the first months of life to 23 years, and the median age of established diagnosis was 3.0 (2.0; 6.0) years, the range — from 0.1 to 38.9 years. The major symptoms of MPS type II in children at the time of diagnosis included musculoskeletal disorders (99.1%), Hurler phenotype 96.4%, short neck was detected in 88.8%, hepatomegaly (based on physical examination findings) in 91.9% of patients, according to abdominal ultrasound data in 87.7% patients, umbilical and inguinal hernias in 82.1% of patients, cardiovascular damage — in 80.3%, chest deformity — 80.3%, contractures of the hand joints (74.5%), and ENT manifestations (62.4%). 151 (85.3%) patients were alive at the time of data collection. ERT was administered to 140 out of 160 (87.5%) patients with MPS type II. Frequent variants in the IDS gene typical for the Russian population were revealed: recombination IDS/ps IDS2 ex3/int7, variants p.Gly374=, p.Arg468Gln, p.Ala85Thr, p.Pro86Leu and p.Arg443Ter. Conclusion. The prevalence of MPS type II in Russian Federation is comparable to data from international registries. The registry-based approach enables the dynamic analysis of the disease’s clinical signs, treatment efficacy evaluation, and planning of healthcare resources. Further expansion of clinical part of the registry, regular data updates, and integration with international registry platforms are crucial for in-depth research and for obtaining more comprehensive data on patients with orphan diseases.
- 2 October 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 25 (4) , 232-247
Open AccessClinical and Epidemiological Characteristics of Patients with Mucopolysaccharidosis Type II (Hunter Syndrome) According to Data from the Russian Registry
Background . The study was conducted based on data from the Russian registry of patients with mucopolysaccharidosis (MPS) type II. There are no similar studies based on analysis of data from the national MPS registry in Russian Federation . Objective . The aim of the study is to conduct a comprehensive analysis of MPS type II epidemiology and phenotypic features in Russian patients using data from the national registry, as well as to compare the obtained results with corresponding data from international registries. Methods. The retrospective, cross-sectional observational study included data from 177 patients with confirmed diagnosis of MPS type II. Data on medical history, clinical, laboratory, and instrumental examination methods, as well as data on enzyme replacement therapy (ERT) over the period from 2008 to March 2026 was analyzed. Results . The prevalence of MPS type II in Russian Federation was 0.1 per 100,000 population, and 0.54 per 100,000 live births (approximately 1 in 185,000 live births). The geographical distribution of patients was uneven. The median age of first symptoms was 1.0 (0; 2.0) years, the range — from the first months of life to 23 years, and the median age of established diagnosis was 3.0 (2.0; 6.0) years, the range — from 0.1 to 38.9 years. The major symptoms of MPS type II in children at the time of diagnosis included musculoskeletal disorders (99.1%), Hurler phenotype 96.4%, short neck was detected in 88.8%, hepatomegaly (based on physical examination findings) in 91.9% of patients, according to abdominal ultrasound data in 87.7% patients, umbilical and inguinal hernias in 82.1% of patients, cardiovascular damage — in 80.3%, chest deformity — 80.3%, contractures of the hand joints (74.5%), and ENT manifestations (62.4%). 151 (85.3%) patients were alive at the time of data collection. ERT was administered to 140 out of 160 (87.5%) patients with MPS type II. Frequent variants in the IDS gene typical for the Russian population were revealed: recombination IDS/ps IDS2 ex3/int7, variants p.Gly374=, p.Arg468Gln, p.Ala85Thr, p.Pro86Leu and p.Arg443Ter. Conclusion. The prevalence of MPS type II in Russian Federation is comparable to data from international registries. The registry-based approach enables the dynamic analysis of the disease’s clinical signs, treatment efficacy evaluation, and planning of healthcare resources. Further expansion of clinical part of the registry, regular data updates, and integration with international registry platforms are crucial for in-depth research and for obtaining more comprehensive data on patients with orphan diseases.
- Open Access
- 2 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (1) , 41-47
Epidemiology of Mucopolysaccharidosis Type II According to the Register of the Russian Federation
Objective: The study aimed to evaluate the epidemiological, clinical, and molecular data of mucopolysaccharidosis type II (MPS II) patients and their outcomes using the national registry of patients in the Russian Federation (RF). Materials and Methods: In the retrospective cohort study, the authors included data from the Russian national registry of MPS II. Results: The prevalence of MPS II in RF is 0.62 per 100 000 live births or 0.09 per 100 000 population with the majority of patients in the Central (n = 36) and the Volga Federal District (n = 35). Males were 157 (99.4%), positive MPS II family history had 47 (29.7%) patients. The median age of the first symptoms was 1.8 (0.8-2.6) years, ranging from 0.1 to 19 years, and the age of diagnosis was 4.0 (2.5; 5.9) years, ranging from 0.1 to 38.9 years. A genetic study was available for the analysis in 116 (73.4%) patients. Single nucleotide variants in the IDS gene were found in 98/116 (84.5%) patients, and 18 further patients (15.5%) had gross rearrangements. About 59/98 (60.2%) patients had missense, 15/98 (15.3%) had frame-shift variants, 12/98 (12.2%) had splice site, and 11/98 (11.2%) had nonsense variants. One (1.0%) patient out of 98 patients had a small deletion. Pathogenic, likely pathogenic variants, and variants with uncertain significance were found in 54 (55.1%), 36 (36.7%), and 8 (8.2%) patients, respectively. About 138 (87.3%) patients received enzyme replacement therapy. Conclusion: The prevalence of MPS II in the RF is higher than that in some European countries and closer to the Asian population. The registry is a convenient tool for disease epidemiology and monitoring. Cite this article as: Buchinskaia NV, Zakharova EY, Koshevaya YS, et al. Epidemiology of mucopolysaccharidosis type II according to the national register of the Russian Federation. Turk Arch Pediatr. 2025;60(1):41-47.
- 2 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (1) , 41-47
Open AccessEpidemiology of Mucopolysaccharidosis Type II According to the Register of the Russian Federation
Objective: The study aimed to evaluate the epidemiological, clinical, and molecular data of mucopolysaccharidosis type II (MPS II) patients and their outcomes using the national registry of patients in the Russian Federation (RF). Materials and Methods: In the retrospective cohort study, the authors included data from the Russian national registry of MPS II. Results: The prevalence of MPS II in RF is 0.62 per 100 000 live births or 0.09 per 100 000 population with the majority of patients in the Central (n = 36) and the Volga Federal District (n = 35). Males were 157 (99.4%), positive MPS II family history had 47 (29.7%) patients. The median age of the first symptoms was 1.8 (0.8-2.6) years, ranging from 0.1 to 19 years, and the age of diagnosis was 4.0 (2.5; 5.9) years, ranging from 0.1 to 38.9 years. A genetic study was available for the analysis in 116 (73.4%) patients. Single nucleotide variants in the IDS gene were found in 98/116 (84.5%) patients, and 18 further patients (15.5%) had gross rearrangements. About 59/98 (60.2%) patients had missense, 15/98 (15.3%) had frame-shift variants, 12/98 (12.2%) had splice site, and 11/98 (11.2%) had nonsense variants. One (1.0%) patient out of 98 patients had a small deletion. Pathogenic, likely pathogenic variants, and variants with uncertain significance were found in 54 (55.1%), 36 (36.7%), and 8 (8.2%) patients, respectively. About 138 (87.3%) patients received enzyme replacement therapy. Conclusion: The prevalence of MPS II in the RF is higher than that in some European countries and closer to the Asian population. The registry is a convenient tool for disease epidemiology and monitoring. Cite this article as: Buchinskaia NV, Zakharova EY, Koshevaya YS, et al. Epidemiology of mucopolysaccharidosis type II according to the national register of the Russian Federation. Turk Arch Pediatr. 2025;60(1):41-47.
- 19 November 2021
- Published by Springer Nature in Journal of Archaeological Method and Theory
- Vol. 29 (3) , 962-988
Crafting Social Networks: the Production of Obsidian Stemmed Tools in the Willaumez Peninsula, Papua New Guinea
- 19 November 2021
- Published by Springer Nature in Journal of Archaeological Method and Theory
- Vol. 29 (3) , 962-988
Crafting Social Networks: the Production of Obsidian Stemmed Tools in the Willaumez Peninsula, Papua New Guinea
- 12 May 2021
- Published by Australian Museum in Technical Reports of the Australian Museum, Online
- Vol. 34, 107-118
Negotiating social identity through material practices with stone. In From Field to Museum—Studies from Melanesia in Honour of Robin Torrence, ed. Jim Specht, Val Attenbrow, and Jim Allen
Negotiating social identity with stone
- 12 May 2021
- Published by Australian Museum in Technical Reports of the Australian Museum, Online
- Vol. 34, 107-118
Negotiating social identity through material practices with stone. In From Field to Museum—Studies from Melanesia in Honour of Robin Torrence, ed. Jim Specht, Val Attenbrow, and Jim Allen
Negotiating social identity with stone
- 18 December 2019
- Published by Australian Museum in Technical Reports of the Australian Museum, Online
- Vol. 29, 1-100
Microscopic revelations: the forms and multiple uses of ground-edged artefacts of the New South Wales Central Coast, Australia
Uses of Australian ground-edged artefacts
- 18 December 2019
- Published by Australian Museum in Technical Reports of the Australian Museum, Online
- Vol. 29, 1-100
Microscopic revelations: the forms and multiple uses of ground-edged artefacts of the New South Wales Central Coast, Australia
Uses of Australian ground-edged artefacts
- 1 August 2016
- Published by Elsevier in Journal of Archaeological Science: Reports
- Vol. 8, 147-163
Detecting early tattooing in the Pacific region through experimental usewear and residue analyses of obsidian tools
- 1 August 2016
- Published by Elsevier in Journal of Archaeological Science: Reports
- Vol. 8, 147-163
Detecting early tattooing in the Pacific region through experimental usewear and residue analyses of obsidian tools
- 4 February 2011
- Published by Australian Museum in Technical Reports of the Australian Museum, Online
- Vol. 21, 1-244
Experimental and archaeological studies of use-wear and residues on obsidian artefacts from Papua New Guinea
- 4 February 2011
- Published by Australian Museum in Technical Reports of the Australian Museum, Online
- Vol. 21, 1-244
Experimental and archaeological studies of use-wear and residues on obsidian artefacts from Papua New Guinea